A detailed evaluation of the current renal response criteria in AL amyloidosis: Is it time for a revision?

Haematologica

Volumn 98, Issue 6, 2013, Pages 988-992

  Leung, Nelson ^a   Glavey, Siobhan V ^b   Kumar, Shaji ^a   Dispenzieri, Angela ^a   Buadi, Francis K ^a   Dingli, David ^a   Lacy, Martha Q ^a   Hayman, Suzanne R ^a   Lust, John A ^a   Russell, Stephen J ^a   Zeldenrust, Steven R ^a   Vincent Rajkumar, S ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEINURIA; RESPONSE TIME; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84878445502     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.079210     Document Type: Article

References (12)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis.[see comment]. N Engl J Med. 2003;349(6):583-96.
2. Comenzo RL. How I treat amyloidosis. Blood. 2009;114(15):3147-57.
3. Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005;46(2): 270-7.
4. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hscTnT) at presentation and changes in N-terminal natriuretic peptide type B (NTproBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116 (18):3426-30.
5. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32 (1):45-59.
6. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104 (6):1881-7.
7. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4): 319-28.
8. Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood. 2005;106(10):3353-7.
9. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-9.
10. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
11. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 2011;29 (6):674-81.
12. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free lightchain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005;36(7):597-600.